Life Science Investing Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
Life Science Investing Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
NextSource Materials Executes Term Sheets with Strategic Investors and Local Capital Partners to Advance Towards Final Investment Decision for its Proposed UAE Battery Anode Facility
